STOCK TITAN

Nasus Pharma: Balyasny reports roughly 9.99% stake

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Nasus Pharma Ltd. (NSRX) ownership amendment reports that Balyasny Asset Management L.P., BAM GP LLC, Balyasny Asset Management Holdings LP, Dames GP LLC and Dmitry Balyasny may each be deemed beneficial owners of 1,170,209 shares, approximately 9.99%. The amount comprises 898,473 common shares and 271,736 shares issuable upon exercise of 898,473 warrants.

The reported percentage is based on 11,713,808 shares outstanding as of August 31, 2026. The warrants are subject to a Beneficial Ownership Limitation that prevents exercise to the extent it would result in ownership above 9.99% of shares outstanding as a result of the exercise. Atlas Private Holdings (Cayman) Ltd. is the direct holder and has the right to receive dividends and sale proceeds.

Beneficial ownership 1,170,209 shares Each of the five reporting persons may be deemed to beneficially own this amount.
Beneficial ownership percentage Approximately 9.99% Based on 11,713,808 shares outstanding as of August 31, 2026.
Common shares 898,473 shares Part of the reported beneficial ownership amount; directly held by Atlas Private Holdings (Cayman) Ltd.
Shares issuable upon warrant exercise 271,736 shares Included in the reported beneficial ownership amount.
Warrants 898,473 warrants Subject to the Beneficial Ownership Limitation.
Shares outstanding 11,713,808 shares As of August 31, 2026.
Beneficial Ownership Limitation regulatory
"subject to the Beneficial Ownership Limitation"
A beneficial ownership limitation is a rule that caps the percentage of a company’s shares an investor can be treated as owning or controlling for voting, regulatory or tax purposes. It matters to investors because it can restrict how many shares a person or group can buy or vote, affect takeover chances, and influence share liquidity and value — like a speed limit that prevents any single driver from taking over the whole road.
Warrants financial
"exercise of 898,473 Warrants"
Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.
investment manager financial
"as the investment manager of Atlas Private Holdings (Cayman) Ltd."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many NSRX shares do the Balyasny reporting persons beneficially own?

Each of the five reporting persons may be deemed to beneficially own 1,170,209 shares, approximately 9.99% of NSRX. The amount consists of 898,473 common shares and 271,736 shares issuable upon exercise of 898,473 warrants. The percentage is based on 11,713,808 shares outstanding as of August 31, 2026.

What is the NSRX warrant ownership limitation?

The warrants cannot be exercised to the extent that exercise would cause the holder to beneficially own more than 9.99% of shares outstanding as a result of the exercise. The filing calls this restriction the Beneficial Ownership Limitation.

Who directly holds the reported NSRX securities?

Atlas Private Holdings (Cayman) Ltd. directly holds the reported securities and has the right to receive dividends and proceeds from their sale. It is identified as an investment management client of Balyasny Asset Management L.P.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





M7071P109

(CUSIP Number)
09/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



BALYASNY ASSET MANAGEMENT L.P.
Signature:/s/ Scott Schroeder
Name/Title:Scott Schroeder / Authorized Signatory
Date:11/16/2026
BAM GP LLC
Signature:/s/ Scott Schroeder
Name/Title:Scott Schroeder / Authorized Signatory
Date:11/16/2026
Balyasny Asset Management Holdings LP
Signature:/s/ Scott Schroeder
Name/Title:Scott Schroeder / Authorized Signatory
Date:11/16/2026
Dames GP LLC
Signature:/s/ Scott Schroeder
Name/Title:Scott Schroeder / Authorized Signatory
Date:11/16/2026
Dmitry Balyasny
Signature:/s/ Dmitry Balyasny
Name/Title:Dmitry Balyasny / Self
Date:11/16/2026

Keep reading